Low seroprevalence of HTLV-I and HTLV-II in patients with a sexually transmitted disease

European Journal of Epidemiology

Volumn 15, Issue 3, 1999, Pages 225-229

  Suligoi, Barbara ^a   Galli, C ^b   Ciuta, S ^a   Decker, R ^c   Albano, F ^c   D'Antuono, A ^c   Calabro G ^c   Caprilli, F ^c   Donofrio, P ^c   Gaddoni, G ^c   Gentili, G ^c   Graifemberghi, S ^c   Latino, M A ^c   Maiello, C ^c   Manca, N ^c   Mignani, E ^c   Priano, L ^c   Puiatti, P ^c   Re, M C ^c   Rossetti, G ^c   Scardigli, F ^c   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ABBOTT DIAGNOSTICS   (Italy)

^c Istituto Superiore di Sanità ^*

Author keywords

HTLV infections ep di tm; Immunoblot; Italy; Recombinant proteins; Sexually transmitted diseases

Indexed keywords

RECOMBINANT PROTEIN;

ADULT; ARTICLE; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOBLOTTING; ITALY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

ADULT; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; RISK FACTORS; RISK-TAKING; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0033053022     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007534600034     Document Type: Article

References (29)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type-C retrovirus particles from fresh and cultured lymphocytes of patients with cutaneous T-cell lymphoma. Proc Natl Sci USA 1980; 77: 7415-7419.
2. Blattner WA, Kalyanaraman VS, Robert-Guroff M, et al. The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T cell leukemia/lymphoma. Int J Cancer 1982; 30: 257-264.
3. de Thè G, Gout O, Gessain A, and Lyon-Caen O. HTLV-I associated myelopathies in Western Europe and tropical Africa: Clinical, epidemiological, and immunovirological observations. In: Blattner WA (ed), Human retrovirology. New York: Raven Press, 1990: 333-347.
4. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calendar A, de Thé G. Antibodies to human T-lymphotropic virus type I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-410.
5. Hjelle B, Appenzeller O, Mills R, Alexander S, Torre-Martinez N, Jahnker R, Ross G. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992; 339: 645-646.
6. Canavaggio M, Leckie G, Allain JP, Steaffens JW, Lurian Y, Brettler D, and Lee H. The prevalence of antibody to HTLV-I/II in United States plasma donors and in United States and French hemophiliacs. Transfusion 1990; 30: 780-782.
7. de Stasio G, Canavaggio M., Rizzi L, et al. Screening for anti-human T-lymphotropic virus antibody in blood donors and polytransfused patients in Apulia (Italy). Vox Sang 1990; 59: 167-171.
8. Lee HH, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen ISY. High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989; 244: 471-475.
9. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 1991; i: 1435-1439.
10. Lemaire JM, Coste J, Barin F, Couroucé AM. Epidemiologic study of anti-HTLV-I/II antibodies in blood donors in metropolitan France. The retrovirus working group of the National Blood Transfusion Society. Rev Fr Transf Hemobiol 1991; 34: 21-34.
11. Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989; 111: 555-560.
12. Vlahov D, Khabbaz RF, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland, USA. J Acquir Immune Defic Syndr 1995; 9: 89-96.
13. Kaplan JE, Khabbaz R, Murphy EL, Hermansesn S, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: Association with viral load. J Acquir Immune Defic Syndr 1996; 12: 193-201.
14. Murphy EL. The epidemiology of HTLV-I: Modes of transmission and their relation to patterns of seroprevalence. In: Blattner WA (ed), Human retrovirology. New York: Raven Press, 1990; 295-305.
15. Khabbaz RF, Onorato IM, Cannon RO, Harley TM, Robert B, Hosein B, Kaplan JE. Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326: 375-380.
16. Wiktor SZ, Cannon RO, Atkinson WL, Lutz B, Hook III EW, Blattner WA, Quinn TC. Infection with human T lymphotropic virus types I and II in sexually transmitted disease clinics in Baltimore and New Orleans. J Inf Dis 1992; 165: 920-924.
17. Figueroa JP, Ward E, Morris J, et al. Incidence of HIV and HTLV-I among sexually transmitted disease clinic attenders in Jamaica. J Acquir Immune Defic Syndr 1997; 15: 232-237.
18. Suligoi B, Giuliani M, Binkin N & the STD Surveillance Working Group. The National STD Surveillance System in Italy: Results of the first year of activity. Intern J STD & AIDS 1994; 5: 93-100.
19. Hartley TM, Malone GE, Khabbaz RF, et al. Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21e antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms. J Clin Microbiol 1991; 29 (6): 1125-1127.
20. Fang C, Layung LG, Sandler SG, Canavaggio M, Laitila V, Lee H. A dot blot immunoassay for serological confirmation and differentiation of HTLV-I and HTLV-II. Transfusion 1992; 32 (suppl. 8): 35S.
21. World Health Organization. Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. Wkly Epidem Rec 1990; 65: 281-288.
22. Lee HH, Galli C, Burczak JD, et al. A multicentric seroepidemiological survey of HTLV-I/II in Italy. Clin Diagn Virol 1994; 2: 139-148.
23. Gardner MJ, Altman DG. Statistics with confidence. Confidence intervals and statistical guidelines. London: British Medical Journal Publishing, 1989.
24. De Rossi A, Bortolotti F, Cadrobbi P, Chieco-Bianchi L. Trends of HTLV-I and HIV infections in drug addicts. Eur J Cancer Clin Oncol 1988; 24: 279-280.
25. Zella D, Morri L, Sala M, et al. HTLV-II infection in Italian drug abusers. Lancet 1990; ii: 575-576.
26. Marinucci G, Di Giacomo C, Dato A, et al. Seropositivity for HTLV-I among Italian prisoners. AIDS 1990; 4: 930-932.
27. Romanò L, Toia C, Tanzi E, et al. Prevalence of HTLV-I and HTLV-II antibodies among Italian injecting drug users. AIDS and related diseases; X anniversary of the Italian National Association against AIDS, 30 November-4 December 1995: 86.
28. The HTLV European Research Network. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. J Acquir Immune Defic Syndr 1996; 13: 68-77.
29. Zanetti AR, Galli C. Seroprevalence of HTLV-I and HTLV-II. N Engl J Med 1992; 326: 1783.